Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1484Neoplasms 1100Carcinoma, Non-Small-Cell Lung 917Prostatic Neoplasms 802Multiple Myeloma 586Colorectal Neoplasms 535Leukemia, Myeloid, Acute 504Lung Neoplasms 489Lymphoma 455Melanoma 454Neoplasm Metastasis 451Lymphoma, Non-Hodgkin 416Leukemia 408Leukemia, Lymphocytic, Chronic, B-Cell 366Ovarian Neoplasms 357Pancreatic Neoplasms 338Precursor Cell Lymphoblastic Leukemia-Lymphoma 334Recurrence 315Head and Neck Neoplasms 298Lymphoma, Follicular 297Myelodysplastic Syndromes 281Carcinoma, Renal Cell 272Glioblastoma 266Brain Neoplasms 265Hodgkin Disease 260Lymphoma, Large B-Cell, Diffuse 255Carcinoma, Hepatocellular 241Lymphoma, Mantle-Cell 219Squamous Cell Carcinoma of Head and Neck 214Stomach Neoplasms 208

Interventions

Bupivacaine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Has results × Peritoneal Cancer × Clear all
NCT03359811 2022-02-18

Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway

M.D. Anderson Cancer Center

Phase 3 Completed
75 enrolled 21 charts

Peritoneal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡